Related Experiment Video
Updated: Apr 16, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation
Lale Erdem-Eraslan1, Ya Gao1, Nanne K Kloosterhof1
1Dept. of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.
Background:
Epidermal growth factor receptor (EGFR) is frequently mutated in various types of cancer. Although all oncogenic mutations are considered activating, different tumour types have different mutation spectra. It is possible that functional differences underlie this tumour-type specific mutation spectrum.
Methods:
We have determined whether specific mutations in EGFR (EGFR, EGFRvIII and EGFR-L858R) have differences in binding partners, differences in downstream pathway activation (gene expression and phosphoproteins), and have functional consequences on cellular growth and migration.
Results:
Using biotin pulldown and subsequent mass spectrometry we were able to detect mutation specific binding partners for EGFR. Differential binding was confirmed using a proximity ligation assay and/or Western Blot for the dedicator of cytokinesis 4 (DOCK4), UDP-glucose glycoprotein glucosyltransferase 1 (UGGT1), MYC binding protein 2 (MYCBP2) and Smoothelin (SMTN). We also demonstrate that each mutation induces the expression of a specific set of genes, and that each mutation is associated with specific phosphorylation patterns. Finally, we demonstrate using stably expressing cell lines that EGFRvIII and EGFL858R display reduced growth and migration compared to EGFR wildtype expressing cells.
Conclusion:
Our results indicate that there are distinct functional differences between different EGFR mutations. The functional differences between different mutations argue for the development of mutation specific targeted therapies.
Insights
Different epidermal growth factor receptor (EGFR) mutations exhibit distinct functional profiles, influencing binding partners and cellular behavior. These findings support the development of targeted therapies specific to individual EGFR mutations in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Epidermal growth factor receptor (EGFR) mutations are common in cancer, with varying mutation spectra across tumor types.
- While considered activating, the functional impact of specific EGFR mutations may differ, potentially explaining tumor-type specificity.
Purpose of the Study:
- To investigate functional differences between specific EGFR mutations (EGFR, EGFRvIII, EGFR-L858R).
- To determine if these mutations differ in binding partners, downstream pathway activation, and cellular effects on growth and migration.
Main Methods:
- Biotin pulldown followed by mass spectrometry to identify EGFR binding partners.
- Proximity ligation assay and Western Blot to confirm differential binding of DOCK4, UGGT1, MYCBP2, and SMTN.
- Gene expression analysis, phosphoprotein profiling, and stably expressing cell lines to assess functional consequences.
Main Results:
- Mutation-specific binding partners for EGFR were identified, including DOCK4, UGGT1, MYCBP2, and SMTN.
- Each EGFR mutation induced a unique set of gene expression changes and distinct phosphorylation patterns.
- EGFRvIII and EGFR-L858R mutations resulted in reduced cellular growth and migration compared to wild-type EGFR.
Conclusions:
- Distinct functional differences exist between various EGFR mutations.
- These functional disparities suggest the need for developing mutation-specific targeted therapies for cancer treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:07MAPK Signaling Cascades
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...